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Objectives: There are over 4,000 trials conducted in people with 
coronavirus disease 2019. However, the variability of outcomes 
and the omission of patient-centered outcomes may diminish the 
impact of these trials on decision-making. The aim of this study 
was to generate a consensus-based, prioritized list of outcomes 
for coronavirus disease 2019 trials.
Design: In an online survey conducted in English, Chinese, Italian, 
Portuguese, and Spanish languages, adults with coronavirus di-
sease 2019, their family members, health professionals, and the 
general public rated the importance of outcomes using a 9-point 
Likert scale (7–9, critical importance) and completed a Best-
Worst Scale to estimate relative importance. Participant com-
ments were analyzed thematically.
Setting: International.
Subjects: Adults 18 years old and over with confirmed or sus-
pected coronavirus disease 2019, their family members, mem-
bers of the general public, and health professionals (including 
clinicians, policy makers, regulators, funders, and researchers).
Interventions: None.
Measurements: None.
Main Results: In total, 9,289 participants from 111 countries 
(776 people with coronavirus disease 2019 or family members, 
4,882 health professionals, and 3,631 members of the public) 
completed the survey. The four outcomes of highest priority for all 
three groups were: mortality, respiratory failure, pneumonia, and 
organ failure. Lung function, lung scarring, sepsis, shortness of 
breath, and oxygen level in the blood were common to the top 
10 outcomes across all three groups (mean > 7.5, median ≥ 8, 
and > 70% of respondents rated the outcome as critically impor-
tant). Patients/family members rated fatigue, anxiety, chest pain, 
muscle pain, gastrointestinal problems, and cardiovascular di-
sease higher than health professionals. Four themes underpinned 
prioritization: fear of life-threatening, debilitating, and permanent 
consequences; addressing knowledge gaps; enabling prepared-
ness and planning; and tolerable or infrequent outcomes.
Conclusions: Life-threatening respiratory and other organ out-
comes were consistently highly prioritized by all stakeholder 
groups. Patients/family members gave higher priority to many 
patient-reported outcomes compared with health professionals. 
(Crit Care Med 2020; XX:00–00)
Key Words: clinical trial; coronavirus; critical care; infection; 
patients; sepsis
As of July 8, 2020, over 11.6 million cases of coronavirus disease 2019 (COVID-19) have been reported, with more than 539,000 deaths in 216 countries (1). The risk 
of death in patients hospitalized for COVID-19 is estimated to 
range from 12% to 33% (2–7). In a study of 5,700 hospitalized 
patients in the United States, 14% required ICU admission, 
and 12% received invasive mechanical ventilation (8). Patients 
with COVID-19 experience fatigue, cough, and dyspnea, which 
impair daily functioning (4, 9–11), and mental health sequelae 
such as depression and anxiety are of concern (12–14).
Substantial resources have been invested in clinical trials in 
COVID-19 (15), with more than 4,000 trials registered on the 
World Health Organization (WHO) International Clinical Trials 
Registry Platform. However, the outcomes included are incon-
sistent, and patient-reported outcomes (16) are infrequently 
measured. Serious clinical outcomes (e.g., mortality, respiratory 
failure) are not always reported, and patient-reported outcomes 
(e.g., cough) are rarely included (17–19). These problems can 
diminish the relevance of the evidence for decision-making by 
patients, health professionals, and regulators.
Three core outcome sets for COVID-19 have been devel-
oped, with respiratory failure and mortality in hospitalized 
patients common to all (20–22). However, only one of these 
initiatives involved consultation with patients and the public 
(n = 27), all of whom were from China. The global COVID-19- 
Core Outcomes Set (COS) initiative convened in March 2020, 
to bring together people with COVID-19 and family members, 
members of the general public, and health professionals, to 
establish consensus-based core outcomes for trials in people 
with confirmed or suspected COVID-19 across the full spec-
trum of disease, in a two-step process. First this study, and then 
an online series of workshops. The aim of this study was to 
identify a prioritized list of outcomes for trials in COVID-19 
and to explain the reasons behind the prioritization decisions.
MATERIALS AND METHODS
We used the Core Outcome Set Standards for Reporting State-
ment (23).
Study Design
We followed the Core Outcome Measures in Effectiveness 
Trials (COMET) methodological framework, which involves 
a Delphi survey and a consensus workshop (24). The con-
sensus workshops will be published separately. This interna-
tional survey was initially designed to be a two-round Delphi 
survey to generate consensus (24). Consensus was achieved in 
round 1, making round 2 unnecessary. Participants prioritized 
outcomes for trials in people with confirmed or suspected 
COVID-19. The survey was conducted in English, Chinese, 
Italian, Spanish, and Portuguese.
Participant Selection and Recruitment
People 18 years old and over with confirmed or suspected 
COVID-19 and their family members, members of the public, 
and health professionals (including clinicians, researchers, and 
policy makers) were eligible. We used multiple recruitment 
strategies to be as broadly inclusive and diverse as possible. 
Respondents were recruited through the Steering Commit-
tee and investigator networks and professional and consumer 
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TABLE 1. Participant Characteristics (n = 9,289)
Characteristic
Patients/Family 
Members,  
n = 776, n (%)
Health  
Professionals,  
n = 4,882, n (%)
Public,  
n = 3,631, n (%)
Participant typea
 Person with suspected COVID-19 420 (54) — —
 Person with confirmed COVID-19 170 (22) — —
 Family/caregiver 312 (40) — —
 Clinician 215 (28) 3,295 (67) —
 Researcher 123 (16) 1,480 (30) —
 Policy maker 23 (3) 69 (1) —
 Other health professional 41 (5) 813 (17) —
Genderb
 Male 253 (33) 1,578 (32) 1,221 (34)
 Female 510 (66) 3,265 (67) 2,381 (66)
Age group (yr)
 18–29 131 (17) 1,190 (24) 763 (21)
 30–39 203 (26) 1,441 (30) 629 (17)
 40–49 213 (27) 1,036 (21) 755 (21)
 50–59 133 (17) 772 (16) 590 (16)
 60–69 74 (10) 370 (8) 599 (16)
 70 and over 22 (3) 73 (1) 295 (8)
Currently in self-isolation/quarantine
 Yes 514 (66) 904 (19) 1,479 (41)
 No 262 (34) 3,978 (81) 2,152 (59)
Language of survey completion
 English 584 (75) 3,004 (62) 2,339 (64)
 Chinese 49 (6) 1,075 (22) 356 (10)
 Italian 59 (8) 253 (5) 362 (10)
 Spanish 47 (6) 298 (6) 307 (8)
 Portuguese 37 (5) 252 (5) 267 (7)
Preexisting/health conditionsa
 High blood pressure/cardiovascular/heart conditions 150 (19) — 718 (20)
 Respiratory condition (e.g., asthma) 123 (16) — 382 (11)
 Diabetes/obesity 120 (15) — 477 (13)
 Other/s 169 (22)  964 (27)
 None 408 (53) — 1,972 (54)
(Continued )
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Symptomsa (suspected or confirmed patients only, n = 590)
 Fatigue 393 (67) — —
 Cough 361 (61) — —
 Fever 312 (53) — —
 Shortness of breath 243 (41) — —
 Loss of taste and/or smell 228 (39) — —
 Nausea, vomiting, diarrhea 202 (34) — —
 Chest pain 201 (34) — —
 Other 223 (38) — —
 None/do not know 67 (11) — —
Complicationsa (suspected or confirmed patients only, n = 590)
 Pneumonia 71 (12) — —
 Organ failure 21 (4) — —
 Sepsis 20 (3) — —
 None 451 (76) — —
 Other 58 (10) — —
Treatmenta (suspected or confirmed patients only, n = 590)
 Antiviral therapy 50 (8) — —
 Oxygen 50 (8) — —
 Hydroxychloroquine/chloroquine 41 (7) — —
 Mechanical ventilation 13 (2) — —
 Other/s 115 (19) — —
 None/do not know 394 (67) — —
Country
 United Kingdom 268 (35) 753 (15) 772 (21)
 China 51 (7) 1,113 (23) 370 (10)
 United States 146 (19) 461 (9) 787 (22)
 Australia 50 (6) 765 (16) 390 (11)
 Italy 58 (7) 280 (6) 355 (10)
 Otherc 206 (27) 1,532 (31) 975 (27)
COVID-19 = coronavirus disease 2019.
a Percentages may not add up to 100 due to multiple selections.
b Prefer not to say: patients /family members 13 (2%), health professionals 39 (1%), and public 29 (1%).
c Other includes 106 countries in descending order of total number of participants: Portugal, Canada, Brazil, Mexico, Spain, Chile, France, Netherlands, Ireland, 
Germany, New Zealand, India, Switzerland, South Africa, Argentina, Belgium, Iceland, Sweden, Nigeria, Colombia, Costa Rica, Singapore, United Arab 
Emirates, Japan, Guatemala, Angola, Korea, Republic of, Saudi Arabia, Lithuania, Uganda, Norway, Denmark, Pakistan, Greece, Poland, Uruguay, Austria, 
Dominican Republic, El Salvador, Malaysia, Turkey, Cameroon, Kenya, Peru, Panama, Egypt, Bangladesh, Ecuador, Islamic Republic of Iran, Iraq, Israel, Gambia, 
Indonesia, Malawi, Philippines, Serbia, Zimbabwe, Albania, Bulgaria, Ethiopia, Jordan, Kuwait, Malta, Paraguay, Russian Federation, Sri Lanka, Côte d’Ivoire, 
Estonia, Honduras, Qatar, Senegal, Trinidad and Tobago, Tunisia, Ukraine, United Republic of Tanzania, Bolivarian Republic of Venezuela, Viet Nam, Marshall 
Islands, Yemen, Afghanistan, Andorra, Antigua and Barbuda, Barbados, Belize, Botswana, Cape Verde, Czech Republic, Finland, Georgia, Hungary, Lebanon, 
Liechtenstein, Luxembourg, Mozambique, Nepal, Oman, Puerto Rico, Romania, Rwanda, Sao Tome and Principe, Slovakia, Slovenia, Sudan, Thailand, Timor-
Leste, and Zambia.
Dashes indicate data not applicable.
TABLE 1. (Continued). Participant Characteristics (n = 9,289)
Characteristic
Patients/Family 
Members,  
n = 776, n (%)
Health  
Professionals,  
n = 4,882, n (%)
Public,  
n = 3,631, n (%)
Clinical Investigation
Critical Care Medicine www.ccmjournal.org 5
organizations using email, social media, and a market research 
company. The University of Sydney provided ethics approval.
Data Collection
Selection of Outcome Domains. We included outcome 
domains from systematic reviews and published core outcome 
sets for COVID-19, after discussion among the Steering Com-
mittee, which included patients and members of the public 
(20–22, 25) (eTable 1, Supplemental Digital Content 1, http://
links.lww.com/CCM/F730) The order of outcomes was ran-
domized. The survey was administered online using Qualtrics 
software (SAP, Provo, UT). The survey was open for 16 days 
from March 31, 2020, to April 16, 2020.
Prioritization of Outcomes. Participants rated the impor-
tance of each of the 25 outcome domains using the Grading of 
Recommendations Assessment, Development, and Evaluation 
process 9-point Likert scale (26). Scores 1–3 indicated “lim-
ited importance,” 4–6 indicated “important but not critical,” 
and 7–9 indicated “critical importance.” Participants could 
enter comments in free-text boxes and suggest new outcomes. 
Participants also completed a Best-Worst Scale survey compris-
ing of five-choice sets, including six of the possible 25 outcomes. 
The Best-Worst Scale survey is a well-established method for 
eliciting relative preferences. The outcomes included in each set 
were determined using a balanced, incomplete block design (27, 
28). Participants selected the most important and least impor-
tant outcome from each block of outcomes presented.
Data Analysis
Quantitative Analysis. We calculated the mean score, median, 
and proportion of participants who rated the outcome from 7 
to 9 (critically important) for each outcome. We calculated the 
scores separately for patients/family, members of the public, 
and health professionals. We compared the “public” and “health 
professional” group with the “patients/family” group using 
mean differences. We did not rely on the normality assumption 
and used nonparametric tests to compare the importance of 
the outcome given by the three groups. The overall differences 
were compared using Kruskal-Wallis tests. If significant dif-
ferences were found, we performed the pairwise comparisons 
Figure 1. Mean scores of patients/family members, health professionals, and the general public (ordered by patient/family scores). Total sample size 
differs for each outcome. Death, cardiovascular disease, shortness of breath, chest pain, and cough (n = 9,289); fever, pneumonia, hospitalization, 
depression, and impact on family (n = 9,072); gastrointestinal problems, fatigue, life participation, muscle pain, and respiratory failure (n = 8,907); 
sepsis/septic shock, taste and smell, anxiety, lung function, and recovery (n = 8,789); and oxygen level in the blood, viral load or clearance, lung scarring 
(fibrosis), hospital-acquired infection (HAI), and organ failure n = 8,653.
Evangelidis et al
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using Mann-Whitney U tests with Bonferroni correction to ad-
just for multiple comparisons. The relative importance score 
was derived using a multinomial logistic regression model. 
Utility functions containing all outcomes and interaction terms 
for participant characteristics were constructed for the Best-
Worst Survey. Following this approach, the mean regression 
coefficients of this function provided the relative importance 
scores for each outcome (27). The regression coefficients have 
the same underlying scale; therefore, for ease of interpretation, 
we used a scale of 1 (least im-
portant) to 9 (most impor-
tant). Statistical analyses were 
conducted using SPSS (Version 
25.0; IBM SPSS Statistics for 
Windows, Armonk, NY) and 
NLOGIT 6 (Econometric Soft-
ware, Plainview, NY). A p value 
of less than 0.05 was consid-
ered statistically significant.
Definition of Consensus. 
The thresholds for consensus 
could not be defined a priori 
because the distribution of 
scores was not known prior to 
data collection. After reviewing 
the results, we set the threshold 
to identify the top 10 outcome 
domains indicated as critically 
important by all three stake-
holder groups on the Likert 
scale. This was based on the pa-
tient/family, public, and health 
professional groups, each hav-
ing mean greater than 7.5, me-
dian greater than or equal to 8, 
and greater than 70% of each 
group rating the outcome as 
“critically important.” The 10 
outcomes of highest priority 
were used to select the proposed 
3 to 5 core outcomes to discuss 
at the consensus workshop.
Qualitative Analysis. 
Survey comments were 
imported into Hyper RE-
SEARCH (ResearchWare Inc, 
version 3.7; Randolph, MA) 
software for data analysis. 
Investigators (N.E., A.T.) used 
thematic analysis to code the 
text and inductively identify 
themes to explain the reasons 
for prioritizing outcomes 
among stakeholder groups.
RESULTS
Participant Characteristics
In total, 9,289 participants from 111 countries completed the 
survey, of whom 776 (8%) were patients with confirmed or 
suspected COVID-19 or their family members, 4,882 (53%) 
were health professionals, and 3,631 (39%) were members 
of the public. The participant characteristics are provided in 
Table 1. The 776 patients/family members were from 40 coun-
tries. Seventy-one of the 590 patients (12%) with suspected or 
Figure 2. Difference in mean scores among patients/family members, public, and health professionals. 
Patients/family members are the reference group. The distance between each value represents the difference 
in mean scores between groups (patients/family members—health professionals; patients/family members—
public). For example, patients/family members rated chest pain higher than health professionals (mean score 
difference of 0.45). Health professionals rated fever higher than patients/family members (mean score 
difference of –0.27). diff = difference, HAI = hospital-acquired infection.
Clinical Investigation
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confirmed COVID-19 reported having pneumonia, 21 (4%) re-
ported organ failure, and 20 (3%) sepsis. Fifty (8%) were treated 
with oxygen and 13 (2%) required mechanical ventilation. Of 
the 4,882 health professionals (from 95 countries), 2,249 (46%) 
were physicians, 1,218 were researchers (25%), 866 (18%) were 
nurses, 78 (2%) were psychologists, 55 (1%) were policymak-
ers, 48 (1%) were social workers, 37 (1%) were industry rep-
resentatives, and 1,153 (24%) were “other health professionals.” 
Among the physicians, 364 (16%) specialized in internal medi-
cine, 320 (14%) were intensive/critical care specialists, 155 (7%) 
were general practitioners, 103 (5%) were emergency physicians, 
101(4%) were infectious disease specialists, 98 (4%) were pul-
monary/respiratory specialists, and 97 (4%) were public health 
physicians, and 1,011 (45%) were “other specialist physicians.” 
The 3,631 members of the general public were from 76 countries.
Absolute Importance Scores
The top four outcomes with the highest mean score for 
patients/family members, health professionals, and the public 
were the same (Fig. 1; eTables 2 and 3, Supplemental Digital 
Content 1, http://links.lww.com/CCM/F730). This included 
death (patients/family: mean 8.2, health professionals: mean 
8.4, and public: mean 8.3); respiratory failure (patients/family: 
8.2, health professionals: 8.4, and public: 8.4); pneumonia 
(patients/family: 7.9, health professionals: 8.1, and public: 8.2); 
and organ failure (patients/family: 7.9, health professionals: 
8.1, and public: 8.1). Lung 
function, lung scarring, sepsis, 
shortness of breath, and ox-
ygen level in the blood were in 
the top ten outcomes for each 
stakeholder group.
Differences in mean 
scores among patients/family, 
health professionals, and the 
public are shown in Figure 2. 
Patients/family rated the fol-
lowing six outcomes higher 
than health professionals on 
the Likert scale: chest pain (ab-
solute mean difference, 0.5; p < 
0.001), fatigue (0.3; p < 0.001), 
muscle pain (0.3; p = 0.003), 
gastrointestinal problems 
(0.3; p = 0.005), anxiety (0.2; 
p = 0.034), and cardiovascular 
disease (0.2; p < 0.001). Health 
professionals rated the follow-
ing four outcomes higher than 
patients/family on the Likert 
scale: fever (0.3; p < 0.001), 
shortness of breath (0.3; 
p < 0.001), respiratory failure 
(0.2; p = 0.002), and cough 
(0.2; p = 0.042).
Relative Preferences—Best-Worst Scale
Patients/family members considered death to be the most im-
portant, followed by respiratory failure, organ failure, lung 
function, and sepsis (Fig. 3). The differences between death 
and respiratory failure were small with preference scores of 
7.5 (95% CI, 7.2–7.9) and 6.6 (95% CI, 6.6–7.4), respectively. 
Death and respiratory failure were also ranked as the top two 
most important outcomes by the public and health profes-
sionals. However, they were of equal importance with prefer-
ence scores for death and respiratory failure being 8.3 (95% 
CI, 8.1–8.5) and 8.2 (95% CI, 8.1–8.4) for the public and 9.0 
(95% CI, 8.8–9.2) and 9.0 (95% CI, 8.8–9.1) for health pro-
fessionals. Shortness of breath the most important patient-
reported outcome for patients/family, the public, and health 
professionals.
The differences in mean preferences scores between patients/
family and health professionals and the public were gener-
ally small, being less than 2.0 (scale 1 to 9) for all outcomes 
(Fig. 4). Compared to patients/family, the most notable differ-
ences were for death (mean differences in relative preference 
scores of –1.3 [95% CI, –1.7 to –0.9] and –2.0 [95% CI, –2.4 to 
–1.6] for the public and health professionals, respectively) and 
respiratory failure (mean differences of –1.1 [95% CI, –1.6 to 
–0.7] and –1.2 [95% CI, –1.6 to –0.8] for the public and health 
professionals, respectively). Impact on family, anxiety, depres-
sion, fatigue, recovery, and life participation were all ranked 
Figure 3. Mean relative importance scores of patients/family members, public, and health professionals based 
on the Best-Worst Scale, ordered by the mean importance scores of patients/family members (error bars are 
95% CI). HAI = hospital-acquired infection.
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as more important by patients/family members compared to 
the public; chest pain, muscle pain, gastrointestinal outcomes, 
and fatigue were ranked as more important by patients/family 
compared to health professionals.
The mean, median, and Best-Worst Scale scores accord-
ing to survey language (English, Chinese, Italian, Spanish, 
and Portuguese) are provided in eTable 4 and eFigure 1 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
F730). The 10 most highly prioritized outcomes by country 
were generally similar. Respiratory failure was in the top two 
for all languages. Based on the mean score, death was first 
in the English survey, third in the Portuguese survey, fourth 
for Chinese, and sixth for the 
Spanish and Italian surveys. 
Subgroup analysis by disease 
severity was not possible due to 
the limited number of patients 
with severe disease.
Additional Outcomes
Thirteen additional outcomes 
were each suggested by 30 or 
more respondents, including 
post-traumatic stress dis-
order (PTSD), anemia/iron, 
delirium, diabetes, cognition, 
immunity and antibodies, diz-
ziness, dysphagia, acute kidney 
injury, financial impact, head-
ache, and physical function.
Themes From Comments
We identified four themes 
underpinning the prioriti-
zation of outcomes, which 
are described below. Selected 
quotations to support each 
theme are provided in eFigure 
2 (Supplemental Digital Con-
tent 1, http://links.lww.com/
CCM/F730).
Fear of Life-Threatening, 
Debilitating, and Permanent 
Consequences. Participants 
gave higher priority to out-
comes that were seen as a threat 
to survival—“(respiratory 
failure) is thought to be the 
main cause of death.” The vis-
ible risk of death explained the 
high priority for mortality—
“you see death coming for 
you” and that you “imagine the 
worse possible scenario, par-
ticularly when you are short 
of breath.” Severe outcomes 
that required isolation or admission to intensive care or in-
vasive interventions were distressing and “could be linked to 
longer-term issues such as PTSD.” Symptoms that “lingered” 
and impaired quality of life (e.g., shortness of breath) were 
given higher priority. For patients, the high prioritization of 
impact on family, depression, and anxiety reflected angst about 
isolation and profound guilt of infecting others. Anxiety was 
also rated high because it exacerbated symptoms—“this un-
certainty causes anxiety and makes breathing harder.”
Addressing Knowledge Gaps. Because of the uncertain tra-
jectory and prognosis of COVID-19, participants gave higher 
priority to outcomes related to disease progression (e.g., 
Figure 4. Difference in mean scores among patients/family members, public, and health professionals based 
on the Best-Worst Scale. Patients/family members are the reference group. diff = difference, HAI = hospital-
acquired infection.
Clinical Investigation
Critical Care Medicine www.ccmjournal.org 9
mortality, respiratory failure, pneumonia, lung function, and 
recovery). Some gave higher priority to outcomes they believed 
were specific to COVID-19 (e.g., respiratory failure, shortness 
of breath) over those regarded to be more general (e.g., anxiety) 
or may have been preexisting.
Enabling Preparedness and Planning. Outcomes were 
given higher priority if they had implications for healthcare 
resource use. Respiratory failure was a high priority because it 
could require admission into intensive care and interventions 
including oxygen, mechanical ventilation, and extracorporeal 
membrane oxygenation—“it informs all measures that should 
be taken (lockdown, production of ventilators, etc.)” Some also 
considered outcomes for decision-making—“this would in-
form my decision to continue very invasive treatment or not.”
Tolerable or Infrequent Outcomes. Participants gave lower 
priority for outcomes such as cough, gastrointestinal symp-
toms, fever, and muscle pain because these were perceived to 
be manageable, uncommon, or transient. Some patients based 
their decisions on whether they had experienced the symptom 
personally.
DISCUSSION
For patients, family members, health professionals, and the 
public, mortality, respiratory failure, pneumonia, organ failure, 
lung function, lung scarring, sepsis, shortness of breath, and 
blood oxygen were the outcomes of highest priority. Mortality, 
respiratory failure, pneumonia, and organ failure of highest 
priority for all three groups. The patient-reported outcome of 
highest priority for all groups was shortness of breath. Hos-
pitalization was in the top 10 for patients/family and health 
professionals. Viral load/clearance was in the top 10 for the 
public. Recovery was the top-rated long-term outcome. The 
top prioritized outcomes reflected the prevailing fear of death 
and debilitating and permanent consequences, uncertainty of 
disease progression, and concerns about the burden of disease 
on health systems.
Mortality and respiratory failure have also been identi-
fied in the three core outcomes set previously established for 
COVID-19 (20–22), albeit with previous initiatives focused 
on hospitalized patients only. The WHO core outcome meas-
ures set for COVID-19 include viral burden and a clinical pro-
gression scale that includes five states: uninfected, ambulatory, 
hospitalized with mild disease, hospitalized with severe disease, 
and death. The “ambulatory” state refers to the patient being 
symptomatic. However, no specific symptoms were identi-
fied. Shortness of breath, recovery (defined as feeling better, 
no longer having symptoms), and chest pain were the three 
patient-reported outcomes of highest importance as identified 
in our survey. Of note, chest pain, fatigue, muscle pain, and 
gastrointestinal problems were rated higher by patients/family 
compared with health professionals. Anxiety was rated higher 
by patients/family compared with both health professionals 
and the general public. People with COVID-19 attributed anx-
iety to the fear and guilt of infecting others and the need to 
be quarantined and isolated from family and support persons. 
Anxiety exacerbated their symptoms, particularly shortness of 
breath. The inclusion of patients and the public brings nuanced 
insights and attention to include outcomes of importance (e.g., 
shortness of breath) that may be underrecognized and not ex-
plicitly included in core outcome sets.
The survey included a large number of participants 
(n = 9,289) from 111 countries, with 47% comprising of 
patients, family members, and the public. The survey was avail-
able in five languages. The data were triangulated by assessing 
both the absolute and relative importance of scores, using four 
measures (mean, median, proportion, and Best-Worst Scale 
score). However, there are some potential limitations. The on-
line survey would have precluded involvement of those who 
do not have access to the internet. Most participants were from 
high-income countries and completed the English language 
survey, and only a small number of patients with severe di-
sease were included. Not all participants completed the entire 
survey; however, we have indicated the number of responses 
for each outcome and of those who completed the Likert rat-
ings and Best-Worst Scale.
CONCLUSIONS
Mortality, respiratory failure, organ failure, sepsis, and short-
ness of breath are of critical importance to people with con-
firmed or suspected COVID-19 and their family members, the 
public, and health professionals. These outcomes will comprise 
the proposed core outcomes to be reviewed and discussed at 
international, online multi-stakeholder consensus workshops 
to establish the core outcome domains for COVID-19. The 
use of outcomes of importance to all stakeholders, including 
patients, the public, and health professionals, can help to im-
prove the relevance of trials to better inform decision-making 
in practice and policy.
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